European Innovation Council Invests €17.5M in Smart Immune: Accelerator Grant and Equity Commitment to Support Revolutionary Technology

Smart Immune SAS, a clinical-stage biotechnology company, has been selected by the European Innovation Council (EIC) to receive €17.5 million in funding to further the development of ProTcell, their revolutionary thymus-empowered T-cell therapy platform.

ProTcell is designed to rapidly and fully re-arm the immune system and has the potential to save countless lives by treating life-threatening cancers and infections. This funding will accelerate the development of this groundbreaking technology and bring it one step closer to becoming available to those who need it most.

The European Innovation Council (EIC) Accelerator Fund, a program designed to empower small and medium-sized enterprises (SMEs), particularly start-ups and spin-out companies to fuel innovation, received nearly 500 applications from all over Europe. After an online interview process, 32 of these applicants were awarded a grant.

Among these, Smart Immune was the only French company to receive an equity commitment in addition to the grant. This commitment promises to be game-changing for the company and its innovative endeavors.

Smart Immune, a company focused on developing innovative therapeutic treatments, has been awarded a €2.5 million grant from the European Innovation Council Accelerator. This grant will help fund their ProTcell Phase I/II clinical trials and is accompanied by an equity investment commitment of up to €15 million to be used towards their CAR T-cell application development and bioproduction scale-up.

With this funding, Smart Immune will be able to move closer to unlocking the potential of their pioneering treatments.

Karine Rossignol, Chief Executive Officer and Co-founder of Smart Immune, has expressed her delight at the European Innovation Council’s recognition of their groundbreaking technology. The investment will help to further the clinical trials in Europe and the US of the ProTcell therapy platform, which has the potential to revolutionize the way life-threatening cancers and infections are treated. Smart Immune is striving to improve survival rates for patients by fully and rapidly re-arming their immune systems.

About Smart Immune

Smart Immune is revolutionizing the field of T-cell therapy with their ProTcell platform. Founded in 2017, this clinical-stage biotechnology company is dedicated to providing next-generation allogeneic T-cell therapies to those suffering from life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies.

By fully and rapidly arming the immune system, Smart Immune’s ProTcell platform is enabling a powerful and effective method of treatment for those in need.

Smart Immune’s ProTcell platform is revolutionizing the fight against cancer and infection, with its Phase I/II clinical trials already underway. ProTcell is an ‘off the shelf’ T-cell medicine, introducing potent, allogeneic T-cell progenitors that are then differentiated by the thymus into fully functional T-cells, allowing for total immune repertoire restoration.

Smart Immune is transforming healthcare with its advanced technology, partnering with renowned medical institutions like Memorial Sloan Kettering Cancer Center in New York and Greater Paris University Hospitals (AP-HP). Headquartered at Paris Biotech Santé, the company is leading the way in revolutionizing healthcare treatments, making life-changing treatments available to all.

Leave a Comment